





Taking the Pain out of Pen Needles

Make prescribing savings quickly with no impact on resources

A cost-effective insulin pen needle without compromise on quality, supported by our **FREE** implementation service.

- In line with NHS England recommendations to spend less than £5 per box, Insupen Original is priced at £3.55 per box¹.
- Average CCG pen needle savings of 25% per annum².
- 700% greater savings when actively implemented using our managed formulary change model³.



Contact us to find out how we help CCGs implement to maximise savings





INSUPEN Original

Available in: 4 lengths and 4 gauges

47% of people with diabetes would be more likely to follow their prescribed regimen if injections were less painful⁶.

GAUGE / LENGTH	PIP CODE
32G / 4mm	415-5313
32G / 6mm	415-5321
32G / 8mm	415-5339
31G / 5mm	415-5347
31G / 6mm	415-5354
31G / 8mm	415-5362
30G / 8mm	415-5370
29G / 12mm	415-5578

£3.55 per box of 100



Universal fit - for use with any standard insulin pen.

Benefits for your patients

Quality Assured

Insupen Original insulin pen needles conforms to ISO 11608 and additional quality checks⁴.

Comfort

Precision engineered to reduce friction points and reduce pain^{4,5}.

Wide internal diameter for efficient insulin flow and administration⁴.

Choice

Choose from 4 lengths and 4 gauges to match patient need.





References:

- 1. Items which should not routinely be prescribed in primary care: Guidance for CCGs version 2, June 2019 NHS England Publishing Approval Reference 000608
- 2. Insulin Pen Needle cost model evaluation. Data on file, Spirit Healthcare, April 2020
- 3. Jim Swift et al, "Implementing formulary change in diabetes", British Journal of Healthcare Management, Vol. 23, No. 4
- 4. Data on file, Spirit Healthcare. Pikdare quality standards and testing data, supplied April 2020
- 5. Comparison of usability and Patient Preference for insulin Pen Needles produced with different production Techniques: "Thin-Wall" Needles compared to "Regular-Wall" Needles: An Open-Label Study, Thorsten Siegmund, M.D., Hannes Blankenfeld, M.D., and Petra-Maria Schumm-Draeger, M.D., Diabetes Technology & Therapeutics. August 2009,11 (8):523-528. doi: 10.1089/dia. 2009. 0048. Published in Volume: 11 Issue 8: August 21, 2009
- 6. AADE Injection Impact Survey, 2007.



24/7 NON-AUTOMATED FREE SUPPORT **0800 881 5423**

Spirit Healthcare, Spirit House, Saffron Way, Leicester, LE2 6UP

T: 0116 286 5000 E: info@spirit-healthcare.co.uk W: www.spirit-healthcare.co.uk